Diagrams of FGFR1 mutants and biochemical characterization. A, schematic representation of FGFR1 K562E mutant constructs. Construct 1, FGFR1 K562E; construct 2, FGFR1 K562E: −FRS2; construct 3, FGFR1 K562E: −Crk; construct 4, FGFR1 K562E: −PLCγ; construct 5, FGFR1 K562E: −FRS2/−Crk; construct 6, FGFR1 K562E: −FRS2/−PLCγ; construct 7, FGFR1 K562E: −Crk/−PLCγ; construct 8, FGFR1 K562E: −FRS2/−Crk/−PLCγ. SP, signal peptide; Ig, immunoglobulin-like domain; TM, transmembrane domain; JM, juxtamembrane domain; TK, tyrosine kinase; CT, C-terminal regulatory tail. B, effects of FGFR1 K562E mutants on ERK signaling in PAC1 VSMC. Left panel, PAC1 stable cell lines were cultured in 10% FBS medium for 24 h and then switched to 0.5% FBS medium overnight. The cells were lysed, and the cell lysates were subjected to Western blot analysis and probed with indicated antibodies. β-Tubulin served as a loading control. The molecular masses are indicated on the left in kilodaltons. Right panel, upper panel, Diagram of the PathDetect transreporting system used in this study (pFA/pFR-Luc; Stratagene). Lower panel, PAC1 cells were transfected with pFA2-CMV and pFR-Luc. The pFA2-dbd plasmid was used as a negative control. After 24 h, the cells were lysed, and luciferase activities were measured. Graphed are the means ± S.D. of triplicate samples. Statistical analysis was performed by using one-way ANOVA test. ***, p < 0.001, compared with the control. All of the results are representative of three separate experiments.